Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children

• ClinicalTrials.gov Identifier: NCT00372541
• Recruitment Status: Completed
• First Posted: September 7, 2006
• Last Update Posted: July 26, 2010
• Sponsor: Makerere University
• Information provided by: Makerere University

Study Description

Brief Summary:

Acute lower respiratory tract infections are a leading cause of morbidity and mortality in sub Saharan Africa. The World Health Organisation (WHO) still recommends intravenous chloramphenicol for the treatment of severe pneumonia in children aged less than five years. However, up to 20% of children fail treatment due to the emergence of resistance by bacteria. Several centers now use ceftriaxone, a third generation cephalosporin, which is reported to be efficacious in the treatment of severe pneumonia. However the high cost of ceftriaxone is too prohibitive to allow for its routine use in resource constrained countries. The purpose of this study is to compare chloramphenicol and ceftriaxone in the treatment of severe pneumonia in children under five.

We hypothesize that 92.7% of children who receive once daily intravenous ceftriaxone (75 mg/kg body weight)for 7 days, will recover from severe pneumonia compared to 80.2 % of those who receive intravenous chloramphenicol (25mg/kg body weight/dose every 6 hours for 7 days).

Condition or disease	Intervention/treatment	Phase
Pneumonia	Drug: ceftriaxone	Phase 3

Detailed Description:

A recent report from the World health Organization showed pneumonia was the leading cause of death in children less than 5 years. WHO recommends intravenous Chloramphenicol 25mg/kg six hourly as the first line drug for the treatment of severe pneumonia in these children. Ceftriaxone 75mg/kg daily is the second line drug.

The efficacy of chloramphenicol for the treatment of severe pneumonia ranges from 80%-84%, while that of ceftriaxone ranges from 85% to 97%. However the high cost of ceftriaxone is too prohibitive to allow for its routine use in resource constrained countries. A study comparing penicillin G plus chloramphenicol and ceftriaxone in the treatment of severe pneumonia in Turkey found that both drugs were equally effective in normalization of the outcome parameters. A recent Cochrane review found no randomized controlled trials comparing both drugs in the treatment of severe forms of pneumonia.

The objective of this study it to compare the efficacy of Ceftriaxone versus Chloramphenicol in the treatment of severe pneumonia in the children under five years of age admitted to Mulago hospital.

This will be a double- blinded randomized controlled trial. Three hundred forty eight children with severe pneumonia will be randomized to receive either intravenous ceftriaxone 75mg/kg/day for seven days or intravenous chloramphenicol 100mg/kg/day for seven days. The primary outcome will mortality and secondary outcomes will be time taken to normalization of respiratory rate, temperature and oxygen saturation.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 348 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double
• Primary Purpose: Treatment
• Official Title: Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children Aged Less Than Five Years at Mulago Hospital: A Randomized Controlled Trial
• Study Start Date: September 2006
• Actual Primary Completion Date: March 2007
• Actual Study Completion Date: March 2007

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

1. Mortality from severe pneumonia by 7th day of treatment

Secondary Outcome Measures :

1. Time to normalisation of respiratory rate
2. Time to normalisation temperature
3. Time to normalisation of oxygen saturation

Eligibility Criteria

• Ages Eligible for Study: 6 Months to 59 Months (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Children aged 6 months to 59months with cough, difficult breathing and lower chest indrawing
• Consent from parent/carer

Exclusion Criteria:

• Children with severe Asthmatic attack
• Allergy to any of the study drugs
• Diagnosis of Pneumocystis JiroveciPneumonia on therapeutic treatment

Contacts and Locations

Locations

Uganda

Department of Paediatrics and Child Health, Mulago Hospital

Kampala, East Africa, Uganda, 256

Department of Paediatrics and Child Health, Makerere University

Kampala, Uganda, P O 7072

Department of paediatrics and child Health,Makerere university

Kampala, Uganda, P O 7072

Department of Paediatrics and Child, Makerere University

Kampala, Uganda, P O 7072

Sponsors and Collaborators

Makerere University

Investigators

• Principal Investigator: Cordelia M Katureebe, MBCHB; Makerere University

More Information

Publications:

Cetinkaya F, Gogremis A, Kutluk G. Comparison of two antibiotic regimens in the empirical treatment of severe childhood pneumonia. Indian J Pediatr. 2004 Nov;71(11):969-72.

Bakeera-Kitaka S, Musoke P, Downing R, Tumwine JK. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann Trop Paediatr. 2004 Sep;24(3):227-35.

Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2004;(2):CD002109. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD002109.

Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods GL, Friedland I. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii59-66.

• ClinicalTrials.gov Identifier: NCT00372541
• Other Study ID Numbers: HD1120041348U
• First Posted: September 7, 2006
• Last Update Posted: July 26, 2010
• Last Verified: July 2010

Keywords provided by Makerere University:

ceftriaxone; chloramphenicol; severe pneumonia; children

Additional relevant MeSH terms:

Pneumonia; Respiratory Tract Infections; Infections; Lung Diseases; Respiratory Tract Diseases; Ceftriaxone; Anti-Bacterial Agents; Anti-Infective Agents